Fibronectin Or Derivative Patents (Class 514/9.3)
  • Patent number: 10787499
    Abstract: Certain embodiments of the invention provide epithelial cell adhesion molecule (EpCAM) binding polypeptides, as well as conjugates and CSANs comprising such polypeptides. Additionally, certain embodiments of the invention also provide methods of using such polypeptides and compounds for molecular imaging and molecularly targeted therapies.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: September 29, 2020
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Benjamin Hackel, Carston R. Wagner, Lawrence A. Stern, Clifford Csizmar
  • Patent number: 10738102
    Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: August 11, 2020
    Assignee: LIB THERAPEUTICS, LLC.
    Inventors: Tracy S. Mitchell, Richard Mealey
  • Patent number: 10472422
    Abstract: Provided herein are tetravalent antibodies that specifically bind to human PSGL-1. Unlike bivalent antibodies, these tetravalent antibodies contain a dimer of two monomers, with each monomer comprising two light chain variable (VL) domains and two heavy chain variable (VH) domains. This format allows for cross-linker/FcR-expressing cell-independent tetravalent antibodies against PSGL-1 that show enhanced efficacy as compared to bivalent PSGL-1 antibodies. These tetravalent antibodies can be used in a variety of diagnostic and therapeutic methods, including without limitation treating T-cell mediated inflammatory diseases, transplantations, and transfusions.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: November 12, 2019
    Assignees: ABGENOMICS INTERNATIONAL INC., BIOALLIANCE C.V.
    Inventors: Rong-Hwa Lin, Shih-Yao Lin, Yu-Ying Tsai
  • Patent number: 10450363
    Abstract: Provided herein are proteins comprising a fibronectin based scaffold (FBS) domain, e.g., 10Fn3 molecules, that bind specifically to a target, and wherein the FBS domain is linked at its C-terminus to a region consisting of PmXn, wherein P is proline, X is any amino acid and wherein n is 0 or an integer that is at least 1 and m is an integer that is at least 1, and wherein the PmXn moiety provides an enhanced property to the FBS domain, e.g., enhanced stability, relative to the protein that is not linked to the PmXn moiety.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: October 22, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventor: Dasa Lipovsek
  • Patent number: 10245328
    Abstract: The present disclosure relates to a magnetic resonance imaging (MRI) contrast agent containing a gadolinium complex, and more specically, to a DO3A-tranexamic acid compound having a structure of a chemical formula 1, or an ester compound thereof, and gadolinium complexes thereof. The DO3A-tranexamic acid compound or the ester compound thereof may be used to prepare gadolinium complexes. The gadolinium complexes exhibit thermodynamic and kinetic stabilities, and show the relaxation rate equal to that of the clinical contrast agent which is currently commercially available. Therefore, the gadolinium complexes can be widely used as an MRI contrast agent.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: April 2, 2019
    Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Tae-Jeong Kim, Yong Min Chang
  • Patent number: 10016452
    Abstract: A formulation for reducing corneal scarring and related eye conditions, is disclosed. The formulation comprises an effective amount of fibromodulin and can be administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: July 10, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Chia Soo
  • Patent number: 9017655
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: April 28, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao Rakestraw, Marco Gottardis, Joan Carboni
  • Publication number: 20150111822
    Abstract: There are provided compositions and methods for modulating stem cell division, in particular, division symmetry. It has been demonstrated that Wnt7a polypeptide fragments promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro, ex vivo, and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 23, 2015
    Inventors: Michael A. Rudnicki, Conrad Florian Bentzinger, Radoslav Zinoviev
  • Publication number: 20150051149
    Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
    Type: Application
    Filed: October 31, 2012
    Publication date: February 19, 2015
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jonathan Davis, Dasa Lipovsek, Ray Camphausen
  • Publication number: 20150030580
    Abstract: The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration.
    Type: Application
    Filed: October 13, 2014
    Publication date: January 29, 2015
    Inventors: DROR SELIKTAR, LIORA ALMANY
  • Publication number: 20150004138
    Abstract: The invention provides a genipin cross-linked fibrin gel. The ratio of genipin to fibrin in the gel ranges from about 0.1:1 to about 10:1 (genipin:fibrin). The gel can be hydrogel. The gel further contains proteins from the extracellular matrix that promote cell growth and density in and around the gel. Also provided is method for repairing tissue defects by administering the gel to site of tissue defect.
    Type: Application
    Filed: September 11, 2014
    Publication date: January 1, 2015
    Inventors: James C. Iatridis, Clare Canal Guterl
  • Patent number: 8921317
    Abstract: A fibrin-based hemostatic agent suitable for both civilian and military use is disclosed. The hemostatic agent comprises (i) nanoparticles to which a plurality of Knob-A recognition sequences are attached, and (ii) coiled-coils of recombinantly-produced human fibrinogen ? and chains and the ? chain globular domain. A delivery system for the hemostatic agent also is disclosed, which additionally comprises means for delivering (i) and (ii) to a wound site. The delivery means may be a CO2 canister or a shaker jet.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: December 30, 2014
    Assignee: BAE Systems Information and Electronic Systems Integration Inc.
    Inventor: Robert A. Burton
  • Publication number: 20140271610
    Abstract: The present invention relates to composition(s) comprising collagen, calcium ions and alginate, wherein the composition polymerizes in situ when contacted with blood. The composition may further comprise an erythrocyte aggregation agent and/or a platelet activation agent. The composition may be formulated into two separate formulations. The first formulation comprises collagen in a calcium-containing solution and a second formulation comprises an aqueous alginate solution. The two formulations can be mixed prior to the contact with blood or mixed coincident with the contact with blood.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 18, 2014
    Applicant: ORTHOVITA, INC.
    Inventor: James San Antonio
  • Patent number: 8835501
    Abstract: This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: September 16, 2014
    Assignee: TopoTarget UK Limited
    Inventors: Richard J. Bastin, Nicholas J. Hughes
  • Publication number: 20140186369
    Abstract: The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. The invention also provides a method of identifying an agent that inhibits neovascularization. The method comprises detecting fibronectin (Fn) matrix assembly by stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A decrease in Fn matrix assembly in the presence of the agent compared to Fn matrix assembly in the absence of the agent is indicative of an agent that inhibits neovascularization. Alternatively, the method of identifying an agent that inhibits neovascularization comprises detecting changes in nuclear architecture in stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent.
    Type: Application
    Filed: February 28, 2014
    Publication date: July 3, 2014
    Applicant: The Regents of The University of Michigan
    Inventors: Stephen J. Weiss, Robert G. Rowe
  • Publication number: 20140187488
    Abstract: Described herein are methods for maintaining PEGylation and inhibiting dePEGylation of polypeptides, such as fibronectin-based scaffold proteins, during storage.
    Type: Application
    Filed: May 15, 2012
    Publication date: July 3, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Bernice Yeung, Jack Wang
  • Patent number: 8728483
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: May 20, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
  • Publication number: 20140107020
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Application
    Filed: September 12, 2013
    Publication date: April 17, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO
  • Patent number: 8697048
    Abstract: The present invention relates to the use of self-assembling peptide amphiphiles to prevent tumor formation by transplanted stem cells. The present invention further relates to the use of self-assembling peptide amphiphiles to treat cancers.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: April 15, 2014
    Assignee: Northwestern University
    Inventors: Li-Ru Zhao, John A. Kessler
  • Publication number: 20140038893
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: August 1, 2013
    Publication date: February 6, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray CAMPHAUSEN, Brent MORSE, Stuart EMANUEL, David FABRIZIO
  • Publication number: 20140004158
    Abstract: Cell attachment coatings for articles such as implantable medical devices and cell culture vessels are disclosed. The coatings include an intermediate coater layer which includes a phosphorous-containing component that is bonded in the coating by reacted photoreactive functional groups. The coating also include a second coated layer including an immobilized ECM protein or peptide that includes an active portion of an ECM protein that is able to serve as an outer layer to contact cells during use. The coatings promoted enhanced cell binding and growth.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 2, 2014
    Inventor: Joseph S. McGonigle
  • Patent number: 8609613
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: December 17, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • Publication number: 20130315889
    Abstract: The present invention relates to protein complexes or scaffold comprising cartilage oligomeric matrix protein (COMP) polypeptides bound to one or more growth factors, and methods of their use in promoting chondrogenesis and/or osteogenesis, and repair of cartilage and bone lesions.
    Type: Application
    Filed: September 14, 2011
    Publication date: November 28, 2013
    Applicant: The Regents of the University of California
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik
  • Patent number: 8591885
    Abstract: Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 26, 2013
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Patrick M. Hughes, Gerald W. Devries
  • Publication number: 20130295081
    Abstract: The presently-disclosed subject matter includes polyurethane composites that include tissue component(s), as well as methods of making such composites and uses thereof. The polyurethane component can comprise a polyisocyanate prepolymer and a polyol. The tissue component can be a polysaccharide. Exemplary composites can be moldable and/or injectable, and can cure into a porous composite that provides mechanical strength and/or supports the in-growth of cells. Inventive composites have the advantage of being able to fill irregularly shaped areas, voids, or the like. Exemplary composites can be used for treating wounds.
    Type: Application
    Filed: April 16, 2013
    Publication date: November 7, 2013
    Inventors: Scott A. Guelcher, Andrea Hafeman, Jeffrey Davidson, Lillian M. Nanney, Elizabeth Adolph
  • Patent number: 8569227
    Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: October 29, 2013
    Assignee: Janssen Biotech, Inc.
    Inventor: Steven Jacobs
  • Patent number: 8524244
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: September 3, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
  • Publication number: 20130217625
    Abstract: Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.
    Type: Application
    Filed: April 11, 2013
    Publication date: August 22, 2013
    Applicant: Amgen Inc.
    Inventor: Amgen Inc.
  • Publication number: 20130216604
    Abstract: A polypeptide for inhibiting, treating or diagnosing metastasis and an use thereof are disclosed, wherein the polypeptide is a polypeptide, a derivative polypeptide, or a mutated polypeptide of a fibronectin-binding domain of dipeptidyl peptidase IV. In addition, a pharmaceutical composition treating or diagnosing metastasis is also disclosed, which comprises the aforementioned polypeptide, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: August 23, 2012
    Publication date: August 22, 2013
    Applicant: National Cheng Kung University
    Inventors: Hung-Chi Chen, Chien-Sheng Chen, Yu-Chuan Lin, Chin-Yun Cheng
  • Publication number: 20130190224
    Abstract: The present invention is directed to various uses of fibronectin binding proteins or polypeptides for treating and preventing fibrosis and fibrosis related conditions. The fibronectin binding proteins and polypeptides are also useful for treating conditions associated with vascular remodeling and cardiac dysfunction.
    Type: Application
    Filed: February 3, 2011
    Publication date: July 25, 2013
    Applicants: MAX-PLANCK-GESELLSCHAFT zur FORDERUNG der WISSENSCHAFTEN e.V., UNIVERSITY OF ROCHESTER
    Inventors: Jane Sottile, Inaam Nakchbandi, Burns C. Blaxall
  • Publication number: 20130184212
    Abstract: The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.
    Type: Application
    Filed: May 26, 2011
    Publication date: July 18, 2013
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, John O'Loughlin, Bernice Yeung, Yihong Zhang
  • Patent number: 8476010
    Abstract: A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, optionally albumin, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: July 2, 2013
    Assignee: APP Pharmaceuticals LLC
    Inventors: Neil P. Desai, Andrew Yang, Sherry Xiaopei Ci
  • Patent number: 8470332
    Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: June 25, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, David Fabrizio, Martin C. Wright, Patrick Gage, John Mendlein
  • Publication number: 20130157948
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Application
    Filed: December 3, 2012
    Publication date: June 20, 2013
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventor: Bristol-Myers Squibb Company
  • Publication number: 20130156819
    Abstract: The present invention relates to peptides or fragments thereof, which peptides bind to mesenchymal stem cells. The present invention also relates to a method for identifying, isolating, specifically selecting and/or enriching mesenchymal stem cells, wherein the peptides, or fragments thereof, are employed for specifically binding to the mesenchymal stem cells. Also, the present invention relates to the use of the peptides of the invention, or fragments thereof, and of the mesenchymal stem cells isolated with the peptides of the invention, or fragments thereof, for treating, injuries and/or degenerated bone, cartilage or tissues.
    Type: Application
    Filed: December 5, 2012
    Publication date: June 20, 2013
    Applicants: Baden-Württemberg Stiftung gGmbH, Eberhard-Karls-Universit°t Tübingen Universit°tsklinikum
    Inventors: Eberhard-Karls-Universit°t Tübingen Universit°tskl, Baden-Württemberg Stiftung gGmbH
  • Publication number: 20130108700
    Abstract: The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 2, 2013
    Applicant: Halscion, Inc.
    Inventor: Halscion, Inc.
  • Publication number: 20130096058
    Abstract: The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.
    Type: Application
    Filed: April 12, 2011
    Publication date: April 18, 2013
    Applicant: MedImmune, LLC
    Inventors: Manuel Baca, Thomas Thisted, Jeffrey Swers, David Tice
  • Publication number: 20130089548
    Abstract: A method for inducing apoptosis of tumoral cells in a patient having cancer cells bearing Cell-adhesion molecule-related/Downregulated by Oncogenes (CDO) receptors and expressing Sonic Hedgehog (SHH), including administering to the patient an effective amount of an agonist of CDO's apoptotic function, wherein the agonist is selected from the group consisting of a CDO fragment, a fusion protein comprising a CDO fragment, an antibody against SHH, and an siRNA which is capable of inhibiting SHH expression, and related CDO fragments, fusion proteins comprising a CDO fragment, antibodies against SHH, and siRNAs which are capable of inhibiting SHH expression.
    Type: Application
    Filed: March 23, 2011
    Publication date: April 11, 2013
    Applicant: NETRIS PHARMA
    Inventors: Patrick Mehlen, Celine Delloye-Bourgeois, Agnes Bernet, Jean Guy Delcros, Pascale Nony
  • Publication number: 20130079280
    Abstract: The present invention provides fibronectin type III (Fn3)-based multimeric scaffolds that specifically bind to one or more specific target antigen. The invention further provides bispecific Fn3-derived binding molecules that bind to two or more target antigens simultaneously, fusions, conjugates, and methods to increase the stability of Fn3-based binding molecules. Furthermore, the present invention is related to a prophylactic, therapeutic or diagnostic agent, which contains Fn3-based multimeric scaffolds.
    Type: Application
    Filed: April 12, 2011
    Publication date: March 28, 2013
    Applicant: Medlmmune, LLC
    Inventors: Manuel Baca, Thomas Thisted, Jeffrey Swers
  • Patent number: 8394924
    Abstract: The present invention features engineered proteins that include a first polypeptide that specifically binds a first target (e.g., a cellular target, such as a cell-surface antigen) and a second polypeptide that selectively binds an activating FcR.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: March 12, 2013
    Assignee: Massachusetts Institute of Technology
    Inventors: K. Dane Wittrup, Shanshan Wu Howland
  • Publication number: 20130012436
    Abstract: The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (IL-23), specifically the p19 subunit of IL-23. The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: February 16, 2011
    Publication date: January 10, 2013
    Inventors: Ruchira Dasgupta, Alex Bush, Lumelle Schneeweis, Linda Engle
  • Publication number: 20130004543
    Abstract: Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, or KGF and fibronectin, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of fibronectin. These protein complexes include synthetic proteins where the growth factor and fibronectin sequences are joined by a linker sequence. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement, skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer.
    Type: Application
    Filed: November 30, 2010
    Publication date: January 3, 2013
    Applicant: Queensland University of Technology
    Inventors: Zee Upton, Derek Van Lonkhuyzen
  • Patent number: 8343501
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: January 1, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao, Marco Gottardis, Joan Carboni
  • Patent number: 8324362
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: December 4, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • Publication number: 20120301393
    Abstract: The present invention refers to novel recombinant proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B). Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component.
    Type: Application
    Filed: December 14, 2010
    Publication date: November 29, 2012
    Inventors: Arnd Steuernagel, Erik Fiedler, Markus Fiedler, Anja Kunert, Joerg Nerkamp, Thomas Goettler, Manja Gloser, Ilka Haenssgen
  • Publication number: 20120263685
    Abstract: The present invention relates to a composition for preventing or treating cancer, which contains one or more selected from the group consisting of human adult stem cells and their secretory products, and to a method of preventing or treating cancer using the same. Particularly, the invention relates to the use of adult stem cells that exhibit the effect of preventing or treating cancer by activating the immune system. The human adult stem cells of the invention are administered by a simple method such as intravenous injection and are highly valuable as a cell therapeutic agent for treating various cancer (tumor) diseases. Thus, the adult stem cells will be highly useful in anticancer studies.
    Type: Application
    Filed: April 7, 2010
    Publication date: October 18, 2012
    Applicant: RNL BIO CO., LTD
    Inventors: Jeong Chan RA, Sung Keun KANG, Sang Kyu WOO, Hwa Young YOUN, Hee Woo LEE, Kyoung Won SEO
  • Publication number: 20120253298
    Abstract: A tissue thickness compensator may generally comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a third layer comprising a third medicament. The tissue thickness compensator may comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a reservoir comprising a third medicament disposed within the reservoir. The medicaments may be independently selected from a haemostatic agent, an anti-inflammatory agent, an antibiotic agent, anti-microbial agent, an anti-adhesion agent, an anti-coagulant agent, a pharmaceutically active agent, a matrix metalloproteinase inhibitor, and combinations thereof. Articles of manufacture comprising the tissue thickness compensator and methods of making and using the tissue thickness compensator are also described.
    Type: Application
    Filed: March 28, 2012
    Publication date: October 4, 2012
    Applicant: Ethicon Endo-Surgery, Inc.
    Inventors: Cortney E. Henderson, Taylor W. Aronhalt, Chunlin Yang, Charles J. Scheib, Venkataramanan Mandakolathur Vasudevan, Mark D. Timmer, Richard W. Timm, Tamara Widenhouse, Steven G. Hall
  • Publication number: 20120231091
    Abstract: Provided is an efficient method of inducing differentiation of a pulp cell into an odontoblast. Also provided is an agent for inducing differentiation capable of inducing differentiation into an odontoblast efficiently. The method of inducing differentiation of a pulp cell into an odontoblast includes using a substance capable of activating a Wnt signaling pathway. Further, the agent for inducing differentiation includes a substance capable of activating a Wnt signaling pathway. Specifically, the substance capable of activating a Wnt signaling pathway is any one selected from sodium perchlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2.
    Type: Application
    Filed: November 16, 2010
    Publication date: September 13, 2012
    Applicant: National University Corporation Okayama University
    Inventors: Takashi Yamashiro, Hiroshi Kurosaka, Noriaki Kawanabe
  • Publication number: 20120220523
    Abstract: The invention relates to the use of a composition comprising at least one corn (Zea mays L.) peptidic hydrolyzate, as an active agent to stimulate and/or restore hair growth, or prevent hair loss. The invention is also relative to the use of this novel active agent to produce a dermato-pharmaceutical composition, intended to stimulate and restore hair growth or limit hair loss. The invention further applies to a cosmetic treatment method intended to prevent or combat the manifestations of hair aging.
    Type: Application
    Filed: November 2, 2010
    Publication date: August 30, 2012
    Applicant: ISP INVESTMENTS
    Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
  • Patent number: 8221765
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: July 17, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar